drugset

drugset / Trial / NCT05745181

Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma

NCT05745181 ↗

Phase 2 Unknown 20 enrolled The Affiliated Hospital of Xuzhou Medical University

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of anti-CD1a CAR-T in the treatment of relapsed refractory acute T-lymphoblastic leukemia/lymphoblastic lymphoma.

Timeline

Start: 2023-02-01
Primary completion: 2026-01-01
Completion: 2026-01-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Anti-CD1a CAR-T	Cell therapy	—	—

Indications